A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study

PURPOSE: Cardiac dysfunction risk associated with intravenous trastuzumab (H IV) treatment may differ in real-world practice versus randomized trials. We investigated cardiac events in patients with HER2-positive early breast cancer (EBC) treated with H IV as adjuvant therapy in routine practice. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Lidbrink, Elisabet, Chmielowska, E., Otremba, B., Bouhlel, A., Lauer, S., Liste Hermoso, M., Nüesch, E., Shing, M., Misra, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418299/
https://www.ncbi.nlm.nih.gov/pubmed/30506110
http://dx.doi.org/10.1007/s10549-018-5058-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418299/
https://www.ncbi.nlm.nih.gov/pubmed/30506110
http://dx.doi.org/10.1007/s10549-018-5058-6

Ejemplares similares